Access the full text.
Sign up today, get DeepDyve free for 14 days.
M Pfreundschuh (2017)
abstr 1549Blood, 130
M Maerevoet (2017)
abstr S469
FL Locke (2017)
abstr 2826Blood, 130
G. Cartron, H. Watier (2017)
Obinutuzumab: what is there to learn from clinical trials?Blood, 130 5
J. Abramson, M. Palomba, L. Gordon, M. Lunning, J. Arnason, Michael Wang, A. Forero, D. Maloney, T. Albertson, Jacob Garcia, Daniel Li, B. Xie, T. Siddiqi (2017)
High Durable CR Rates in Relapsed/Refractory (R/R) Aggressive B-NHL Treated with the CD19-Directed CAR T Cell Product JCAR017 (TRANSCEND NHL 001): Defined Composition Allows for Dose-Finding and Definition of Pivotal CohortBlood, 130
M. Pfreundschuh, K. Christofyllakis, B. Altmann, M. Ziepert, M. Haenel, A. Viardot, A. Neubauer, G. Held, L. Truemper, M. Dreyling, L. Kanz, M. Hallek, N. Schmitz, T. Heintges, C. Kölbel, A. Buecker, C. Ruebe, D. Hellwig, C. Berdel, V. Poeschel, N. Murawski (2017)
RADIOTHERAPY TO BULKY DISEASE PET‐NEGATIVE AFTER IMMUNOCHEMOTHERAPY CAN BE SPARED IN ELDERLY DLBCL PATIENTS: RESULTS OF a PLANNED INTERIM ANALYSIS OF THE FIRST 187 PATIENTS WITH BULKY DISEASE TREATED IN THE OPTIMAL > 60 STUDY OF THE DSHNHLHematological Oncology, 35
(2017)
Interimreportfrom a phase 2 multicenter study of tazemetostat , an EZH 2 inhibitor , in patients withRrelapsed or refractory B - cell non - hodgkin lymphomas
M Pfreundschuh, N Murawski, K Christofyllakis (2017)
Excellent outcome of elderly patients with Favourable-prognosis DLBCL treated with 4 cycles CHOP/Chlip-14 plus 8 applications of Rituximab and a PET-based intensification strategy that includes involved-site radiotherapy (IS-RT): results of the first 120 patients of the OPTIMAL〉60 trial of the DshnhlBlood, 130
T. Lamy, G. Damaj, P. Soubeyran, E. Gyan, G. Cartron, K. Bouabdallah, R. Gressin, J. Cornillon, A. Banos, K. Dû, M. Benchalal, M. Moles, S. Gouill, J. Fleury, P. Godmer, H. Maisonneuve, E. Deconinck, R. Houot, K. Laribi, J. Marolleau, O. Tournilhac, B. Branger, A. Devillers, J. Vuillez, T. Fest, P. Colombat, V. Costes, V. Szablewski, M. Béné, V. Delwail (2018)
R-CHOP 14 with or without radiotherapy in nonbulky limited-stage diffuse large B-cell lymphoma.Blood, 131 2
F. Morschhauser, G. Salles, P. McKay, H. Tilly, A. Schmitt, J. Gerecitano, P. Johnson, S. Gouill, M. Dickinson, C. Fruchart, T. Lamy, A. Chaidos, W. Jurczak, Stephen Opat, J. Radford, P. Zinzani, S. Assouline, G. Cartron, A. Clawson, N. Picazio, S. Ribich, S. Blakemore, J. Larus, H. Miao, P. Ho, V. Ribrag (2017)
INTERIM REPORT FROM A PHASE 2 MULTICENTER STUDY OF TAZEMETOSTAT, AN EZH2 INHIBITOR, IN PATIENTS WITH RELAPSED OR REFRACTORY B‐CELL NON‐HODGKIN LYMPHOMASHematological Oncology, 35
(2008)
Phase II study of rituximab plus three cycles of CHOP and involved - fieldradiotherapyforpatientswithlimited - stageaggressive B - cell lymphoma : Southwest OncologyGroup study 0014
M. Crump, S. Neelapu, U. Farooq, E. Neste, J. Kuruvilla, J. Westin, B. Link, A. Hay, J. Cerhan, Liting Zhu, S. Boussetta, Lei Feng, M. Maurer, L. Navale, J. Wiezorek, W. Go, C. Gisselbrecht (2017)
Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study.Blood, 130 16
D. Persky, J. Unger, C. Spier, B. Stea, M. LeBlanc, Matthew McCarty, L. Rimsza, R. Fisher, T. Miller (2008)
Phase II study of rituximab plus three cycles of CHOP and involved-field radiotherapy for patients with limited-stage aggressive B-cell lymphoma: Southwest Oncology Group study 0014.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 26 14
J. Abramson, B. McGree, S. Noyes, Sean Plummer, C. Wong, Yi-Bin Chen, E. Palmer, T. Albertson, J. Ferry, I. Arrillaga-Romany (2017)
Anti-CD19 CAR T Cells in CNS Diffuse Large-B-Cell Lymphoma.The New England journal of medicine, 377 8
(2008)
Phase II study of rituximab plus three cycles of CHOP and involved fieldradiotherapyforpatientswithlimited-stageaggressive B-cell lymphoma: Southwest OncologyGroup study
S. Neelapu, F. Locke, N. Bartlett, L. Lekakis, D. Miklos, C. Jacobson, I. Braunschweig, O. Oluwole, T. Siddiqi, Yi Lin, J. Timmerman, P. Stiff, J. Friedberg, I. Flinn, A. Goy, B. Hill, Mitchell Smith, A. Deol, U. Farooq, P. Mcsweeney, J. Muñoz, I. Avivi, J. Castro, J. Westin, J. Chavez, A. Ghobadi, K. Komanduri, R. Levy, E. Jacobsen, T. Witzig, P. Reagan, A. Bot, J. Rossi, L. Navale, Yi-zhou Jiang, J. Aycock, M. Elias, David Chang, J. Wiezorek, W. Go (2017)
Axicabtagene Ciloleucel CAR T‐Cell Therapy in Refractory Large B‐Cell LymphomaThe New England Journal of Medicine, 377
M. Pfreundschuh, A. Ho, E. Cavallin-ståhl, M. Wolf, R. Pettengell, I. Vášová, A. Belch, J. Walewski, P. Zinzani, W. Mingrone, S. Kvaløy, O. Shpilberg, U. Jaeger, M. Hansen, C. Corrado, A. Scheliga, M. Loeffler, E. Kuhnt (2008)
Prognostic significance of maximum tumour (bulk) diameter in young patients with good-prognosis diffuse large-B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab: an exploratory analysis of the MabThera International Trial Group (MInT) study.The Lancet. Oncology, 9 5
(2017)
Single agentoralselinexorexhibitsdurableresponsesinrelapsed/ refractory diffuse large B-cell lymphoma (DLBCL) of both GCB and non-GCB subtypes: the phase 2B SADAL study
F. Locke, J. Westin, D. Miklos, A. Herrara, C. Jacobson, Jennifer Lee, J. Rossi, A. Bot, A. Xue, L. Navale, J. Aycock, J. Wiezorek, Z. Roberts (2017)
Phase 1 Results from ZUMA-6: Axicabtagene Ciloleucel (axi-cel; KTE-C19) in Combination with Atezolizumab for the Treatment of Patients with Refractory Diffuse Large B Cell Lymphoma (DLBCL)Blood, 130
(2017)
Phase 1 ResultsfromZUMA - 6 : AxicabtageneCiloleucel ( axi - cel ; KTE - C 19 ) inCombina - tion with Atezolizumab for the Treatment of Patients with RefractoryDiffuseLargeBCellLymphoma ( DLBCL )
(2017)
A comparison of one year outcomes in ZUMA-1 (axicabtagene ciloleucel) andSCHOLAR-1inpatientswithrefractory,aggressivenonHodgkinlymphoma(NHL).Blood
(2008)
Sixversuseight cycles of bi - weekly CHOP - 14 with or without rituximab in elderly patients with aggressive CD 20 + B - cell lymphomas : arandomisedcontrolledtrial ( RICOVER - 60 )
SS Neelapu (2017)
abstr 579Blood, 130
M. Pfreundschuh, J. Schubert, M. Ziepert, R. Schmits, M. Mohren, E. Lengfelder, M. Reiser, C. Nickenig, M. Clemens, N. Peter, C. Bokemeyer, H. Eimermacher, A. Ho, M. Hoffmann, R. Mertelsmann, L. Trümper, L. Balleisen, R. Liersch, B. Metzner, F. Hartmann, B. Glass, V. Poeschel, N. Schmitz, C. Ruebe, A. Feller, M. Loeffler (2008)
Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60).The Lancet. Oncology, 9 2
S. Schuster, J. Svoboda, E. Chong, S. Nasta, A. Mato, Ö. Anak, J. Brogdon, Iulian Pruteanu-Malinici, V. Bhoj, D. Landsburg, M. Wasik, B. Levine, S. Lacey, J. Melenhorst, D. Porter, C. June (2017)
Chimeric Antigen Receptor T Cells in Refractory B‐Cell LymphomasThe New England Journal of Medicine, 377
S. Neelapu, F. Locke, N. Bartlett, L. Lekakis, P. Reagan, D. Miklos, C. Jacobson, I. Braunschweig, O. Oluwole, T. Siddiqi, Yi Lin, M. Crump, J. Kuruvilla, E. Neste, U. Farooq, L. Navale, W. Go, J. Wiezorek, C. Gisselbrecht (2017)
A Comparison of One Year Outcomes in ZUMA-1 (axicabtagene ciloleucel) and SCHOLAR-1 in Patients with Refractory, Aggressive Non-Hodgkinlymphoma (NHL)Blood, 130
M. Maerevoet, J. Vermaat, M. Canales, R. Casasnovas, E. Neste, A. Goy, B. Hill, C. Thieblemont, M. Cruz, F. Cavallo, G. Follows, S. Choquet, R. Gurion, R. Bouabdallah, U. Jaeger, Á. Nagy, J. Kuruvilla, K. Warzocha, N. Kalakonda, P. Caimi, S. Bakhshi, M. Ku, N. Hamad, H. Veelken, E. Matczak, Xiwen Ma, J. Saint-Martin, J. Shah, M. Kauffman, S. Shacham, J. Zijlstra (2018)
Single Agent Oral Selinexor Demonstrates Deep and Durable Responses in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) in Both GCB and Non-GCB Subtypes: The Phase 2b Sadal StudyBlood
Combined-modality treatment with chemo-immunotherapy and radiotherapy produces excellent outcomes in early-stage, non-bulky diffuse large B‑cell lymphoma, and reducing toxicity of therapy is a major concern, especially in elderly patients. In a recent trial, elderly patients with non-bulky (<7.5 cm) in complete metabolic remission after four courses of therapy (rituximab, cyclophosphamide, doxorubicine, vincristine, prednisone [R‑CHOP-14] based) were spared additional chemotherapy and went on to receive four cycles of rituximab only, while all other patients continued on chemo-immunotherapy. The 2‑year overall survival was 98%, which matches historical controls. In another analysis from the same trial, elderly patients with bulky disease in positrone emission tomography (PET) based CR (complete remission) after six cycles of chemo-immunotherapy were spared radiotherapy, while PET-positive patients were irradiated. This approach resulted in a significant reduction (42%) of radiotherapy compared to historical controls without compromising efficacy. Radiotherapy could also be omitted in patients of any age with limited stage, non-bulky disease in another trial, with a 5-year event-free survival of 89% and an overall survival of 92%. Another burning issue is enhancing efficacy in relapsed and refractory diffuse large B‑cell lymphoma. Arguably the most exciting approach in this area is chimeric-antigen-receptor T‑cell therapy. Recent trials have shown nearly 10-fold increases in complete responses compared to historical controls, and most importantly, a high percentage (40%) of durable remissions after one year of follow-up. As in other advances in immunotherapy, toxicity is a major concern. Cytokine release syndrome occurs frequently (1–18% grade 3–4) and management is complex, sometimes requiring admission to intensive care and often including the interleukin-6 receptor antibody tocilizumab.
memo - Magazine of European Medical Oncology – Springer Journals
Published: May 28, 2018
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.